Humanwell Healthcare Group Co

Humanwell Healthcare Group Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Humanwell Healthcare Group Co (600079.SS) as of Oct 30, 2026 is 3.82 B CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 3.09 B CNY — a change of 23.76% (higher).

EBITDA

3.82 BCNY

YoY

23.76%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Humanwell Healthcare Group Co is 2025 3.82 B CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Humanwell Healthcare Group Co was 2024 3.09 B CNY. It decreases by 23.76% higher compared to the previous year.

The Humanwell Healthcare Group Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
2.11 B CNY
Jan 1, 2019
2.16 B CNY
Jan 1, 2020
2.44 B CNY
Jan 1, 2021
2.57 B CNY
Jan 1, 2022
3.91 B CNY
Jan 1, 2023
3.83 B CNY
Jan 1, 2024
3.09 B CNY
Jan 1, 2025
3.82 B CNY
The Humanwell Healthcare Group Co EBITDA history
YEAREBITDAYoY
3.82 BCNY+23.76%
3.09 BCNY-19.41%
3.83 BCNY-1.81%
3.91 BCNY+52.04%
2.57 BCNY+5.45%
2.44 BCNY+12.87%
2.16 BCNY+2.08%
2.11 BCNY-35.16%
3.26 BCNY+116.50%
1.51 BCNY+40.08%
1.08 BCNY+24.89%
860.86 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Humanwell Healthcare Group Co Stock analysis

What does Humanwell Healthcare Group Co do? Humanwell Healthcare (Group) Co., Ltd. generates revenue through the research and development, production, and sale of a diverse portfolio of medical products. The company’s offerings are categorized into chemical drugs, chemical raw material medicines, traditional Chinese medicines, biological medicines, and others, alongside the provision of medical instruments. This broad product range allows the firm to serve various healthcare needs across its operational scope. The company distributes its products in both domestic market and to overseas markets, indicating a dual-channel sales strategy that captures value from local and international customers. By engaging in the full lifecycle of medical product creation, from R&D to final sale, Humanwell Healthcare (Group) Co., Ltd. monetizes its extensive capabilities and wide distribution network to drive financial performance. Humanwell Healthcare Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humanwell Healthcare Group Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Humanwell Healthcare Group Co is 3.82 B CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Humanwell Healthcare Group Co changed from 3.09 B CNY to 3.82 B CNY, representing a 23.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Humanwell Healthcare Group Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Humanwell Healthcare Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Humanwell Healthcare Group Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Humanwell Healthcare Group Co